Publication | Open Access

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Pembrolizumab Versus PaclitaxelGastrointestinal OncologyMedicineGastroenterologySurgeryAdvanced GastricCancer TreatmentOncologyRadiation OncologyPhase 3